Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Donald Danforth Plant Science Center has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are split between 2 distinct examiners, ensuring that each matter is reviewed by a different individual. This distribution across 2 distinct examiners provides the center with two separate points of contact at the office. Both pending actions are situated within 1 distinct art unit, suggesting a concentrated technical focus for these plant science filings.
BANERJEE, KOYELI is the busiest examiner for this portfolio, currently holding 1 pending office action. This represents one of the 2 pending office actions currently active. Having 2 distinct examiners within 1 distinct art unit allows the center to see how different individuals apply the same art unit standards. Practitioners should use the insights from both of the 2 pending office actions to develop a more effective prosecution strategy within this 1 distinct art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BANERJEE, KOYELI | 1 | 50.0% | +0.0% |
| DICKENS, AMELIA NICOLE | 1 | 47.6% | +21.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18692138 | ANTIMICROBIAL CaNCR PEPTIDE VARIANTS | BANERJEE, KOYELI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18392130 | ANTIMICROBIAL PEPTIDES AND MODIFICATIONS THEREOF | DICKENS, AMELIA NICOLE | 13d |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18692138 | ANTIMICROBIAL CaNCR PEPTIDE VARIANTS | BANERJEE, KOYELI | — | §101§102DP | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18392130 | ANTIMICROBIAL PEPTIDES AND MODIFICATIONS THEREOF | DICKENS, AMELIA NICOLE | 1645 | §102Other | Non-Final OA | 13d | Pending | Dec 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial